ENLIVEN THERAPEUTICS, INC.

Press Releases Enliven Therapeutics, Inc.

Equities

ELVN

US29337E1029

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
23.9 ^USD	-2.41%		+13.86%	+72.69%

Apr. 11	Enliven Therapeutics, Inc. Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia	CI
Apr. 09	Enliven Therapeutics, Inc. Appoints Lori Kunkel to Board of Directors	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia	Apr. 11	AQ
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors	Apr. 09	AQ
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024	Mar. 28	AQ
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates	Mar. 19	AQ
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update	Mar. 14	AQ
Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference	Feb. 27	AQ
Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update	Nov. 09	AQ
Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress	23-08-10	AQ
Enliven Therapeutics : Material Agreement - Form 8-K	23-06-26	PU
Enliven Therapeutics : REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Form 8-K	23-06-23	PU
Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies	23-03-16	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW